Product Introduction

• The first approved Class II medical device of its kind for oral ulcers and esophageal mucositis caused by radiotherapy and chemotherapy (including ADC, targeted therapy, and immunotherapy), and for improving swallowing and feeding difficulties.

• Officially recommended by the China Anti-Cancer Association (CACA) Guidelines

• Patient Guide for Integrated Rehabilitation of Esophageal Cancer

• Gastrointestinal Protection – CACA Technical Guidelines for Integrated Cancer Diagnosis and Treatment

 Indicated Patients

• Patients undergoing radiotherapy or chemotherapy for head and neck tumors (e.g., nasopharyngeal carcinoma, oral cancer, etc.)

• Patients undergoing radiotherapy or chemotherapy for thoracic tumors (e.g., esophageal cancer, lung cancer, breast cancer, etc.)

• Patients with hematologic malignancies (experiencing mucositis as an adverse reaction)

• Patients with esophageal cancer (including pre-surgical feeding obstruction in early stage, anastomotic stricture and reflux esophagitis post-surgery, as well as dysphagia and painful feeding obstruction in mid-to-late stage)